CliffBio
small molecule

FELBAMATE

FELBAMATE

Loss of exclusivity—loss of exclusivity
CompanyTaro Pharmaceutical Industries →See this company's full patent-cliff portfolio

Drug detail

Brand nameFELBAMATE
Active ingredientFELBAMATE
Strength600MG/5ML
Dosage formSUSPENSION
RouteORAL
ModalitySmall molecule
FDA approvalJune 2017
Marketing statusRX

More from Taro Pharmaceutical Industries

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.